Article info
PDFImage of the moment
After discharges following compound muscle action potential in CASPR2 antibody-related disease
- Correspondence to Dr Dimitrios Parissis, AHEPA Hospital, 2nd Department of Neurology, Aristotle University of Thessaloniki Faculty of Health Sciences, Thessaloniki 541 24, Central Macedonia, Greece; dparissis{at}gmail.com
Citation
After discharges following compound muscle action potential in CASPR2 antibody-related disease
Publication history
- Accepted January 27, 2021
- First published March 3, 2021.
Online issue publication
January 10, 2022
Article Versions
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Occult bowel cancer presenting as Morvan syndrome
- Neuromyotonia: a skin-deep problem
- Morvan’s fibrillary chorea: a paraneoplastic manifestation of thymoma
- LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
- Piso-hamate hiatus syndrome in a patient with Riche-Cannieu anastomosis
- THE NEUROMUSCULAR JUNCTION DISORDERS
- Myasthenia gravis and other neuromuscular junction disorders
- Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy
- Nodes, paranodes and neuropathies
- Excitability properties of motor axons in patients with spontaneous motor unit activity